Cargando…
Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
OBJECTIVE: Metabolic activation of the innate immune system governed by interleukin (IL)-1β contributes to β-cell failure in type 2 diabetes. Gevokizumab is a novel, human-engineered monoclonal anti–IL-1β antibody. We evaluated the safety and biological activity of gevokizumab in patients with type...
Autores principales: | Cavelti-Weder, Claudia, Babians-Brunner, Andrea, Keller, Cornelia, Stahel, Marc A., Kurz-Levin, Malaika, Zayed, Hany, Solinger, Alan M., Mandrup-Poulsen, Thomas, Dinarello, Charles A., Donath, Marc Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402269/ https://www.ncbi.nlm.nih.gov/pubmed/22699287 http://dx.doi.org/10.2337/dc11-2219 |
Ejemplares similares
-
Inhibition of IL-1β Improves Fatigue in Type 2 Diabetes
por: Cavelti-Weder, Claudia, et al.
Publicado: (2011) -
Successful Use of Omalizumab in an Inadequately Controlled Type 2 Diabetic Patient With Severe Insulin Allergy
por: Cavelti-Weder, Claudia, et al.
Publicado: (2012) -
The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure
por: Harouki, Najah, et al.
Publicado: (2017) -
Glycemia and Atherosclerotic Cardiovascular Disease: Exploring the Gap Between Risk Marker and Risk Factor
por: Nahmias, Avital, et al.
Publicado: (2020) -
Nontraditional Markers of Glycemia: Associations with microvascular conditions
por: Selvin, Elizabeth, et al.
Publicado: (2011)